Ron Squarer
Chairman presso ADC THERAPEUTICS SA
Patrimonio netto: 7 M $ in data 31/03/2024
Profilo
Ron Squarer is currently the Chairman at ADC Therapeutics SA since 2020 and the Chairman at Deciphera Pharmaceuticals, Inc. since 2019.
He is also a Director at Deciphera Pharmaceuticals LLC.
Additionally, he serves as an Independent Director at Travere Therapeutics, Inc. since 2017.
In his former positions, Mr. Squarer was the Chief Executive Officer & Director at Array BioPharma, Inc. from 2012 to 2019.
Prior to that, he worked as the Chief Commercial Officer & Senior Vice President at Hospira, Inc. from 2010 to 2011 and as the Senior Vice President-Business Development at Mayne Pharma Ltd.
from 2006 to 2007.
He also held a position at Smithkline Beecham Plc as a Principal.
Mr. Squarer completed his undergraduate studies at the University of California, Berkeley.
He also holds an MBA from the Kellogg School of Management.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
ADC THERAPEUTICS LTD
1.83% | 02/01/2024 | 1 506 898 ( 1.83% ) | 7 M $ | 31/03/2024 |
17/05/2023 | 22 375 ( 0.03% ) | 172 511 $ | 31/03/2024 | |
16/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Ron Squarer
Società | Posizione | Inizio |
---|---|---|
TRAVERE THERAPEUTICS, INC. | Director/Board Member | 12/04/2017 |
DECIPHERA PHARMACEUTICALS, INC. | Chairman | 03/08/2023 |
ADC THERAPEUTICS SA | Chairman | 01/04/2020 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Director/Board Member | 01/12/2019 |
Precedenti posizioni note di Ron Squarer
Società | Posizione | Fine |
---|---|---|
ARRAY TECHNOLOGIES, INC. | Chief Executive Officer | 01/08/2019 |
HOSPIRA, INC. | Corporate Officer/Principal | 01/02/2012 |
Mayne Pharma Ltd.
Mayne Pharma Ltd. Pharmaceuticals: OtherHealth Technology Mayne Pharma Ltd. manufactures pharmaceutical products. It distributes generic injectables for the oncology market. The company's competitors include Sandoz, Bedford Labs, and Ebewe. It was founded in November 2005 and is headquartered in Melbourne, Australia. | Corporate Officer/Principal | 01/01/2007 |
Smithkline Beecham Plc
Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK. | Corporate Officer/Principal | - |
Formazione di Ron Squarer
University of California, Berkeley | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
ADC THERAPEUTICS SA | Health Technology |
TRAVERE THERAPEUTICS, INC. | Health Technology |
DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Smithkline Beecham Plc
Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK. | Health Technology |
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Hospira, Inc.
Hospira, Inc. Pharmaceuticals: MajorHealth Technology Hospira, Inc. provides injectable drugs and infusion technologies. It offers drugs, IV sets and clinical integration, infusion pumps, clinical software and implementation services. The company was founded on September 16, 2003 and is headquartered in Lake Forest, IL. | Health Technology |
Mayne Pharma Ltd.
Mayne Pharma Ltd. Pharmaceuticals: OtherHealth Technology Mayne Pharma Ltd. manufactures pharmaceutical products. It distributes generic injectables for the oncology market. The company's competitors include Sandoz, Bedford Labs, and Ebewe. It was founded in November 2005 and is headquartered in Melbourne, Australia. | Health Technology |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Ron Squarer